GTX-RT in Borderline Resectable Pancreatic Cancer

Phase 2 Terminated 9 enrolled H. Lee Moffitt Cancer Center and Research Institute

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more chemotherapy can increase the chances that the participant's pancreatic tumor can be removed completely.

Timeline

Start: 2013-02
Primary completion: 2014-09
Completion: 2014-10

Outcome

Outcome not reported

Stopped: “Lack of pre-treatment tissue to make the study plan feasible.”

Publications

Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol. 2015 Oct;117(1):159-64. doi: 10.1016/j.radonc.2015.07.018. Epub 2015 Jul 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	750 mg/m2	Oral
Subject	Docetaxel	Small molecule	30 mg/m2	—
Subject	Gemcitabine	Small molecule	750 mg/m2	Intravenous
Background	fluorouracil	Small molecule	—	—